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Emerging mechanisms and novel targets in
allergic inflammation and asthma
Scott T. Weiss
Editorial summary
Airway inflammation is key to the severity and
persistence of asthma. Recent studies have revealed
novel immune mechanisms that target dendritic cells, T
helper 2 cytokines, regulatory T cells, and type 2 innate
lymphoid cells in allergic inflammation, as well as novel
approaches that target airway smooth muscle in
asthma. These advances inform the development of
new targeted treatments for allergic inflammation and
asthma with the potential to provide therapeutic
benefit.
Asthma and allergic inflammation
Asthma is defined by airway hyper-responsiveness and
inflammation. The disorder is syndromic, without a
clear defining feature such that some are reluctant to
call it one disease. Epidemiologic studies suggest that
the prevalence of severe asthma in the USA is approxi-
mately 8% and the disorder costs the US healthcare
system more than 12 billion US dollars per year in
hospitalizations, emergency room visits, and days lost
from work and school [1]. In addition, the disease can
progress to the development of chronic obstructive
lung disease or chronic obstructive pulmonary disease.
On-going allergic inflammation is one of the key reasons
for asthma persistence and severity.
In mild-to-moderate asthma, the predominant inflam-
matory response in the airway is T helper 2 (Th2)-type
inflammation (also known as type 2 (T2) inflammation),
which is driven by CD4+ helper T cells that express the
cytokines IL-13, IL-4, and IL-5 and is associated with el-
evated levels of immunoglobulin E (IgE) and eosinophils
in the airways. In more severe asthma, several inflamma-
tory phenotypes exist, often simultaneously. These in-
clude the previously mentioned T2 inflammation, but
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also Th17 inflammation, which is a neutrophilic inflam-
matory response and, in a small number of cases, a
pauci-granulocytic type of inflammation with neither
eosinophils nor neutrophils. This latter type of inflam-
mation may not be subject to immune control. T2
inflammation is present in all three types of asthma
(mild, moderate, and severe). Th17 inflammation can
also be seen in either moderate or severe asthma, and
pauci-granulocytic inflammation is only seen in severe
asthma [2].
Traditional treatment for mild intermittent asthma is an
as-needed, short-acting, beta-2 adrenergic receptor agon-
ist (beta-2 agonist). Beta-2 agonists are the largest class of
drugs used to treat asthma, but have remained controver-
sial due to poor clinical responses and potentially
life-threatening adverse effects. For mild persistent
disease, inhaled corticosteroids with a short-acting beta
agonist are used for treatment. For moderate and severe
disease, inhaled corticosteroids are combined with a long-
acting beta-2 agonist. Patients with the most severe
disease may require oral steroids on a regular basis and all
patients may need oral steroids during an exacerbation.
Patients with mild disease tend not to take their medica-
tions as prescribed, often using them only when they have
symptoms, rather than to prevent symptoms. Patients
with more severe disease regularly take their prescribed
medications but often do not get symptom relief. Clearly,
new medicines for asthma need to be developed.
Recently, there has been a proliferation of studies that
have revealed the mechanisms underlying allergic
inflammation and asthma, and are providing possible
novel approaches for treatment. These novel mecha-
nisms target dendritic cells (DCs), type 2 innate lymph-
oid cells (ILC2s), regulatory T (Treg) cells, and airway
smooth muscle, or, potentially, all of these. Below, I
discuss current immune therapies for asthma, emerging
mechanisms and targets for the treatment of allergic
inflammation and asthma, and the implications and
challenges for medicine.
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Currently available immune therapies: advantages
and limitations
The involvement of the vitamin D receptor in asthma
susceptibility was identified in linkage and fine-mapping
studies. Vitamin D is a potent immune modulator,
fine-tuning the immune system to respond appropriately to
allergic inflammation. By downregulating the function of
DCs and upregulating Treg cells, vitamin D acts as a
rheostat on the immune response. The vitamin D receptor
is also expressed on airway smooth muscle where higher
concentrations of vitamin D relax the smooth muscle and
prevent its proliferation [3]. Vitamin D also upregulates the
absorption of inhaled corticosteroid across the airway
epithelium [4]. Clinical trial data unequivocally support the
use of vitamin D in childhood asthma, and one study
estimated that the effect was equivalent to that of inhaled
corticosteroids, in terms of reducing asthma exacerbations,
as measured by hospitalizations and emergency room visits
[5].
Monoclonal antibodies to IL-5 and to a combination
of IL-4 and IL-13 have been developed. These drugs
reduce eosinophil numbers, reduce oral steroid use, and
reduce asthma exacerbations in severe asthma [2].
Monoclonal antibodies have also been developed to
another type 2 cytokine, thymic stromal lymphopoietin
(TSLP), which was implicated in asthma using genome-
wide association studies (GWAS), and these TSLP
monoclonal antibodies were recently tested in a clinical
trial [6]. Additional monoclonal antibodies targeting
both the innate and the adaptive immune pathways are
currently in development. These drugs are very expen-
sive but are now available for the treatment of severe
asthma, which represents 3–10% of the population of
adults with asthma. The application of vitamin D or
monoclonal antibodies in clinical practice has been
minimal due to questions about efficacy (vitamin D) and
cost (monoclonal antibodies).
Novel mechanisms and targets for allergic
inflammation
Since the IL33 gene was implicated in asthma via
GWAS, its immunologic function as an alarmin cytokine
has been defined. Much work has gone into determining
how alarmin cytokines (IL-25 and IL-33) activate ILC2
cells [7]. ILC2 cells are not only involved in mucosal
homeostasis but are also involved in the initiation of
inflammatory responses. Wallrapp and colleagues
recently showed that the neuropeptide receptor gene
Nmur1 was highly expressed in murine ILC2 cells, and
that, after IL-25 stimulation, the ligand of NMUR1,
neuromedin U (NMU), activated ILC2 cells in vitro and
in vivo [8]. Co-administration of NMU and IL-25
strongly enhanced allergic inflammation in vivo [8]. One
concern, as with many of these immune mechanisms, is
whether blocking this response would have untoward
effects on infection. Clearly, more investigation is
needed as this response is seen in T2 asthma and so
might be a viable pathway to the treatment of the
disease, although a drug is still a long-term prospect.
There have also been advances in understanding the
regulation of antigen-presenting cells in allergic inflam-
mation. Mechanistic target of rapamycin (mTOR) is a
serine/threonine protein kinase that regulates DC
function by different mechanisms depending on the type
of DC. mTOR promotes type 1 interferon production in
plasmacytoid DCs that express CD103, and reduces
pro-inflammatory cytokine production by classical DCs
that express CD11b [9]. As with vitamin D, there are a
variety of other immune processes influenced by mTOR,
such as the control of effector T cell number, B cell
response, and potentially other immune processes such
as those involved in allergic inflammation. Sinclair and
co-workers recently showed that mTOR regulated both
metabolism and accumulation of CD103+ DCs (plasma-
cytoid DCs) and alveolar macrophages in the lung in
mouse models [9]. Although the numbers of
mTOR-deficient CD11b + DCs (classical DCs) in the
lung were not altered, these cells were metabolically
reprogrammed to shift the balance from eosinophilic
Th2 inflammation to a neutrophilic Th17 response. This
cellular reprograming was shown to be dependent on
classical DCs that both produced IL-23 and increased
fatty acid oxidation, both of which are allergic inflamma-
tory markers [9]. These findings suggest that targeting
classical DCs might be useful for the treatment of
allergic inflammation, but once again further studies are
needed before a drug can be developed.
The beta-2 adrenergic receptors are G protein-coupled
receptors (GPCRs). A specific type of GPCR, the
Gq-coupled receptor, is important in controlling airway
muscle tone. Recently, inhibitors of the Gq protein, such
as FR900359, have been developed and have been tested
in mouse, pig, and human airway tissue [9]. FR900359
prevented bronchoconstriction without effects on blood
pressure and heart rate [10]. Further testing of
FR900359 and other Gq receptor blockers may reveal
these inhibitors to be the first new powerful bronchodi-
lators for many years. These preliminary studies need to
be followed up by phase I clinical trials and toxicity
profiling, so we are still many years away from having
these novel Gq protein inhibitors in the clinic.
Implications for medicine: challenges and future
directions
Genomic discoveries have led to a new understanding of
allergic inflammation, and these new approaches and
targets for the treatment of asthma and allergic inflam-
mation have great potential. However, there are also
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concerns. First, the cost to the consumer of novel
immune therapies is likely to be high. This is certainly
true for monoclonal antibodies. Second, and related to
the cost issue, do we really know enough about who is
likely to respond to these immune therapies? Asthma
sub-phenotyping is still relatively primitive, with mild,
moderate, and severe disease classifications, and we need
improved application of molecular phenotyping as it
relates to specific drug treatment responses. For
example, vitamin D seems to work better for children
than adults and for those with a milder form of the
disease. While those with severe asthma represent a
disproportionate share of the care burden, we still need
to understand the utility of novel treatments not only
for those with severe disease but also for those with
mild-to-moderate disease. Ultimately, to truly advance
precision medicine for allergic inflammation and asthma
we need to be able to deliver these new immune therap-
ies to greater numbers of patients at a reduced cost.
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